- Home
- OGEN vs NCNA Comparison
OGEN vs NCNA Comparison
Compare OGEN & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGEN
- NCNA
- Stock Information
- Founded
- OGEN 1996
- NCNA 1997
- Country
- OGEN United States
- NCNA United Kingdom
- Employees
- OGEN N/A
- NCNA N/A
- Industry
- OGEN Biotechnology: Pharmaceutical Preparations
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- OGEN Health Care
- NCNA Health Care
- Exchange
- OGEN Nasdaq
- NCNA Nasdaq
- Market Cap
- OGEN 4.6M
- NCNA 4.5M
- IPO Year
- OGEN N/A
- NCNA 2017
- Fundamental
- Price
- OGEN $4.28
- NCNA $0.05
- Analyst Decision
- OGEN
- NCNA Buy
- Analyst Count
- OGEN 0
- NCNA 2
- Target Price
- OGEN N/A
- NCNA $25.00
- AVG Volume (30 Days)
- OGEN 599.0K
- NCNA 162.0M
- Earning Date
- OGEN 05-09-2025
- NCNA 06-02-2025
- Dividend Yield
- OGEN N/A
- NCNA N/A
- EPS Growth
- OGEN N/A
- NCNA N/A
- EPS
- OGEN N/A
- NCNA N/A
- Revenue
- OGEN N/A
- NCNA N/A
- Revenue This Year
- OGEN N/A
- NCNA N/A
- Revenue Next Year
- OGEN N/A
- NCNA N/A
- P/E Ratio
- OGEN N/A
- NCNA N/A
- Revenue Growth
- OGEN N/A
- NCNA N/A
- 52 Week Low
- OGEN $3.12
- NCNA $0.03
- 52 Week High
- OGEN $75.60
- NCNA $10.79
- Technical
- Relative Strength Index (RSI)
- OGEN 43.10
- NCNA 37.23
- Support Level
- OGEN $3.12
- NCNA $0.04
- Resistance Level
- OGEN $9.60
- NCNA $0.06
- Average True Range (ATR)
- OGEN 1.04
- NCNA 0.01
- MACD
- OGEN -0.12
- NCNA 0.03
- Stochastic Oscillator
- OGEN 17.90
- NCNA 59.60
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.